• Patient-Derived Gastric Cancer Assembloids: Modeling Tumor-S

  2026-05-27

  This study introduces a patient-derived gastric cancer assembloid system integrating tumor organoids with matched stromal cell subpopulations, more accurately recapitulating tumor microenvironment complexity. The approach enables nuanced analysis of drug response and resistance mechanisms, supporting advances in personalized cancer therapy research.

• Sulfo-Cy3 Azide: Bioconjugation Reagent for Advanced Neuroge

  2026-05-27

  Sulfo-Cy3 azide stands apart as a hydrophilic, photostable bioconjugation reagent, enabling high-efficiency fluorescent labeling in fully aqueous systems. Its superior performance in mapping neurodevelopmental gradients translates to robust, reproducible imaging of complex neuronal populations.

• EdU Imaging Kits (488): Unveiling Proliferation Pathways in

  2026-05-26

  Explore how EdU Imaging Kits (488) enable sensitive, non-destructive DNA synthesis detection for cell proliferation assays. This in-depth article uniquely connects advanced click chemistry workflows to emerging cancer biology, empowering researchers with actionable insights.

• Annexin V as a Precision Phosphatidylserine Binding Protein

  2026-05-26

  Harnessing Annexin V, human recombinant, as a high-affinity phosphatidylserine binding protein enables precise, quantitative apoptosis detection in advanced cell death research. This guide offers actionable workflows, troubleshooting strategies, and evidence-driven protocol enhancements for translational and mechanistic studies.

• Optimizing Histology with the Hematoxylin and Eosin Staining

  2026-05-25

  The Hematoxylin and Eosin Staining Kit (SKU K1142) offers a ready-to-use, reproducible solution for tissue morphology visualization in histopathology and cytology research. It is best suited for applications in paraffin-embedded or frozen tissue section staining and should not be used for diagnostic or clinical decision-making.

• Cefiderocol’s Superior In Vitro Activity Against Resistant E

  2026-05-25

  A recent multicenter study demonstrates that cefiderocol maintains high in vitro activity against European Enterobacterales, including strains resistant to meropenem and β-lactam/β-lactamase inhibitor combinations. This work provides critical comparative data for researchers and clinicians managing multidrug-resistant Gram-negative infections.

• Protease Inhibitor Cocktail: Precision in Protein Extraction

  2026-05-24

  The Protease Inhibitor Cocktail (EDTA-Free, 200X in DMSO) empowers researchers to safeguard protein integrity during extraction, even in cation-sensitive assays. Its tailored, EDTA-free formulation is indispensable for advanced post-translational modification studies and complex immunoprecipitation workflows.

• Valemetostat in Relapsed/Refractory NHL: Phase 1 Efficacy an

  2026-05-23

  This multicentre phase 1 study establishes the clinical activity and manageable safety profile of valemetostat, a dual EZH2/EZH1 inhibitor, in relapsed or refractory non-Hodgkin lymphoma. The research provides foundational data on optimal dosing and highlights epigenetic targeting as a viable strategy in lymphoma therapy.

• HotStart 2X Green qPCR Master Mix: Precision in Gene Quantif

  2026-05-22

  HotStart™ 2X Green qPCR Master Mix enables researchers to achieve highly specific, reproducible nucleic acid quantification, even with complex or low-abundance targets. Its antibody-mediated hot-start Taq polymerase and optimized SYBR Green formulation streamline workflows for gene expression analysis, RNA-seq validation, and challenging clinical assays.

• FITC Goat Anti-Rabbit IgG (H+L): Quantitative Fluorescence M

  2026-05-22

  Explore how the FITC Goat Anti-Rabbit IgG (H+L) Antibody revolutionizes quantitative immunofluorescence by enabling ultra-sensitive, reproducible assays. This article delivers a scientific deep dive into its mechanisms, unique advantages, and evidence-based protocol optimization.

• Circ_0001944 Regulates FXR/TLR4 and Ferroptosis in NiONP Fib

  2026-05-21

  This study uncovers how hsa_circ_0001944 mitigates nickel oxide nanoparticle-induced collagen deposition in hepatic stellate cells by regulating the FXR/TLR4 signaling pathway and ferroptosis. The findings clarify molecular links between non-coding RNA, metabolic nuclear receptor signaling, and regulated cell death in liver fibrosis, providing a mechanistic basis for FXR agonist–based research strategies.

• SAG: Strategic Hedgehog Pathway Activation for CNS Regenerat

  2026-05-21

  This article explores Smoothened Agonist (SAG) as a next-generation tool for translational researchers aiming to modulate the Hedgehog pathway across neuroregeneration and immune models. We dissect mechanistic insights, highlight sex-dependent immune modulation, and deliver strategic guidance for designing robust, clinically relevant studies—bridging recent reference breakthroughs with actionable experimental protocols.

• Ciclesonide in Experimental Asthma: Protocols & Performance

  2026-05-20

  Harness Ciclesonide’s unique prodrug activation and potent anti-inflammatory action to elevate your asthma and allergic rhinitis research. This article details reproducible workflows, troubleshooting strategies, and practical advances from ERAD-hijacking technology, with protocol enhancements and data-driven tips to maximize the reliability of your results.

• Multi-Omics Reveals ARID1A-Driven Resistance in Melanoma

  2026-05-20

  This study uses integrative multi-omics to unravel the molecular networks underlying resistance to BRAF/MAPK inhibitors in melanoma, especially in the context of ARID1A loss. The findings provide a detailed roadmap for understanding adaptive and acquired resistance, highlighting actionable nodes within the MAPK and immune pathways.

• Ruxolitinib Induces Apoptosis via DRP1 Inhibition in ATC

  2026-05-19

  This study reveals that Ruxolitinib phosphate (INCB018424) triggers both apoptosis and GSDME-dependent pyroptosis in anaplastic thyroid carcinoma (ATC) by transcriptionally inhibiting DRP1-mediated mitochondrial fission. The findings establish a novel mechanistic link between JAK1/2-STAT3 pathway inhibition and mitochondrial dynamics, highlighting new therapeutic angles for aggressive thyroid cancers.

16099 records 1/1074 page Next 12345 下5页 Last page